Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00749697
NCT00749697
Unknown
Not Applicable

Investigating Absorbed Radiation Dose Delivered to Differentiated Thyroid Cancer Metastases Following Administration of Fixed Activity of Radioactive Iodine

Royal Marsden NHS Foundation Trust1 site in 1 country10 target enrollmentMay 2008
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsThyroid CarcinomaMetastatic Sites Lung Bone Nodal

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Thyroid Carcinoma
Sponsor
Royal Marsden NHS Foundation Trust
Enrollment
10
Locations
1
Primary Endpoint
The primary outcome measure is to correlate the predicted dose from the tracer study with the actual absorbed dose measure on the therapeutic scan
Last Updated
17 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

The main purpose of the study is to establish a relationship between the administered activity of the radioiodine and absorbed dose in the tumor sites.

Detailed Description

Study Design - the assessment of patients with multiple tumour sites with metastatic thyroid cancer to correlate the administered activity to absorbed dose. Patients will receive the standard therapy dose of 5.5 GBq as per the hospital policy and there will be no change for the protocol purpose.

Registry
clinicaltrials.gov
Start Date
May 2008
End Date
July 2010
Last Updated
17 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •age above 18
  • •histological confirmation of the differentiated thyroid carcinoma available
  • •WHO performance score 0-2
  • •metastatic sites lung and/or bone and/or nodal (radiologically measurable disease \> 1 cm)
  • •life expectancy \> 6 months
  • •patient has undergone total/near total thyroidectomy
  • •no past history of sensitivity/reaction to 1311

Exclusion Criteria

  • •non iodine concentrating tumours
  • •received chemotherapy or radiotherapy in 6 weeks
  • •pregnant or breast feeding patients
  • •iodine contrast injection in last 3 months

Outcomes

Primary Outcomes

The primary outcome measure is to correlate the predicted dose from the tracer study with the actual absorbed dose measure on the therapeutic scan

Secondary Outcomes

  • The secondary outcomes will be to assess the response at 6 months post therapy in each patient

Study Sites (1)

Loading locations...

Similar Trials

Terminated
Not Applicable
Measuring the Effect of Radiation Therapy on Patient Activity LevelsHead and Neck CancerProstate CancerBreast CancerLung Cancer
NCT02694380University of Pittsburgh32
Completed
Not Applicable
PROMISE Substudy to Assess For Effective Dose of Radiation (PROMISE-SAFER) Specific Aim 3bChest PainCoronary Artery DiseaseAngina
NCT01890525Kaiser Permanente20
Completed
Phase 1
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male SubjectsHealthy
NCT01442831Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)6
Completed
Not Applicable
The Characterisation of RT Caries.Head and Neck CancerRadiotherapy Side Effect
NCT03397823King's College London102
Unknown
Not Applicable
Dose-effect Relationship Between microRNAs in Peripheral Blood and Radiation InjuryRadiation Injuries, Experimental
NCT03928782Affiliated Hospital to Academy of Military Medical Sciences8